These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 35680804)

  • 1. [Inhibitory Effect of Interference with PD-L1 Expression on B-cell lymphoma in Mice].
    Shi QQ; Zhu M; Sun X; Ni J; Sun M; Gu J; Wu W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):771-777. PubMed ID: 35680804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of PD-L1 in lymphoma and its effect on lymphoma proliferation and chemotherapy resistance].
    Li Y; Wang J; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):366-70. PubMed ID: 23628034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of shRNA targeting mouse CD99L2 gene in a murine B cell lymphoma in vitro and in vivo.
    Liu F; Zhang G; Liu F; Zhou X; Chen X; Han X; Wu Z; Zhao T
    Oncol Rep; 2013 Apr; 29(4):1405-14. PubMed ID: 23338758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells.
    Yang X; Fang D; Li M; Chen J; Cheng Y; Luo J
    Med Sci Monit; 2021 Mar; 27():e929431. PubMed ID: 33764958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
    Hara T; Miyake H; Hinata N; Fujisawa M
    Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
    Marzec M; Zhang Q; Goradia A; Raghunath PN; Liu X; Paessler M; Wang HY; Wysocka M; Cheng M; Ruggeri BA; Wasik MA
    Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20852-7. PubMed ID: 19088198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-γ-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA.
    Padmanabhan S; Zou Y; Vancurova I
    Methods Mol Biol; 2020; 2108():211-220. PubMed ID: 31939183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma.
    Liu X; Zhang Y; Han Y; Lu W; Yang J; Tian J; Sun P; Yu T; Hu Y; Zhang H; Huang P; Liu P
    Mol Oncol; 2020 May; 14(5):1028-1044. PubMed ID: 32157792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect and mechanism of gene therapy of lentivirus mediated RhoA shRNA on ovarian cancer xenograft in vivo].
    Jiang WY; Kang JL; Wang XX; Yang WJ; Nie ML; Zhou C
    Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):778-83. PubMed ID: 24406137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition and apoptosis of human B-cell lymphoma in vitro and in vivo by Bcl-2 short hairpin RNA.
    Liu Y; Shen Y; Qin C; Shi Y; Rong G; Yu X
    Oncol Rep; 2013 Jan; 29(1):244-52. PubMed ID: 23076380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer.
    Hu R; Zhou B; Chen Z; Chen S; Chen N; Shen L; Xiao H; Zheng Y
    Front Immunol; 2021; 12():722188. PubMed ID: 35111150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma.
    Tamai K; Nakamura M; Mizuma M; Mochizuki M; Yokoyama M; Endo H; Yamaguchi K; Nakagawa T; Shiina M; Unno M; Muramoto K; Sato I; Satoh K; Sugamura K; Tanaka N
    Cancer Sci; 2014 Jun; 105(6):667-74. PubMed ID: 24673799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
    Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
    Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Conditional medium of gastric cancer mesenchymal stem cells promotes PD-L1 expression in gastric cancer cells and tumor growth via upregulating VGLL4].
    Ding Y; Zhu W; Wang Q; Chen B; Wang M; Zhao Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):321-327. PubMed ID: 35583061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 18. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
    Wang QM; Lian GY; Song Y; Huang YF; Gong Y
    Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
    Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
    Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells.
    Xing S; Chen S; Yang X; Huang W
    J BUON; 2020; 25(4):1875-1882. PubMed ID: 33099927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.